Novo Nordisk A/S (NVO) Stock Score, Valuation & Financial Research
Novo Nordisk A/S is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 63/100.
Quick answer for NVO
Novo Nordisk A/S currently has a Wall Street Score of 63/100. The stored market price is $42.53. Its financial score is 23/100. Its valuation score is 97/100. These figures are a research snapshot, not a buy or sell recommendation.
What Novo Nordisk A/S does
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens
NVO financial snapshot
- Wall Street Score:
- 63/100
- Current price:
- $42.53
- Market capitalization:
- $188.86B
- Revenue:
- $50.02B
- Net income:
- $18.61B
- Free cash flow:
- $4.42B
- Cash:
- $3.22B
- Total debt:
- $22.33B
- EPS:
- 3.52
- P/E ratio:
- 12.1x
- Financial score:
- 23/100
- Valuation score:
- 97/100
- Revenue score:
- 44/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $4.42B, showing positive cash generation.
- The balance sheet shows $3.22B of cash versus $22.33B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 97/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 23/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NVO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.